We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
(-13%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-6.55%
Top 10 Holdings %
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
5.7
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
9.8
quarters
Top 10 Avg Time Held Equity only
5.7
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$40.3M |
| 2 |
argenx
ARGX
|
+$39.9M |
| 3 |
Revolution Medicines
RVMD
|
+$39.2M |
| 4 |
Immunovant
IMVT
|
+$29.2M |
| 5 |
RayzeBio, Inc. Common Stock
RYZB
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$68.3M |
| 2 |
Vir Biotechnology
VIR
|
+$48M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$46.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$35.7M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$33.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.21% |
| 2 | Miscellaneous | 0.79% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Amicus Therapeutics
FOLD
| $337M | 11.23% |
27,692,917
+30,000
| +0.1% | +$387K |
2014 Q1
38 quarters
|
|
2
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $220M | 7.35% |
10,088,385
| – | – |
2020 Q4
11 quarters
|
|
|
3
Immunovant
IMVT
$6.09B
| $146M | 4.88% |
3,814,691
+1,290,908
| +51% | +$29.2M |
2022 Q4
3 quarters
|
|
4
DELISTED
Arcellx
ACLX
| $142M | 4.75% |
3,965,978
-50,419
| -1% | -$1.74M |
2022 Q2
5 quarters
|
|
5
DELISTED
Nuvalent
NUVL
| $113M | 3.78% |
2,463,451
+268,630
| +12% | +$11.9M |
2021 Q3
8 quarters
|
|
6
DELISTED
Soleno Therapeutics
SLNO
| $90.7M | 3.03% |
3,074,542
+866,789
| +39% | +$5.25M |
2023 Q2
1 quarter
|
|
|
LIAN
7
DELISTED
LianBio American Depositary Shares
LIAN
| $85.8M | 2.86% |
57,558,451
| – | – |
2021 Q4
7 quarters
|
|
8
DELISTED
Akero Therapeutics
AKRO
| $81.9M | 2.73% |
1,619,425
-321,250
| -17% | -$15M |
2022 Q3
4 quarters
|
|
9
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $78.1M | 2.61% |
4,256,104
+631,922
| +17% | +$13.2M |
2021 Q2
9 quarters
|
|
10
Aldeyra Therapeutics
ALDX
$54.6M
| $75.8M | 2.53% |
11,350,085
| – | – |
2015 Q1
34 quarters
|
|
|
11
argenx
ARGX
$51.1B
| $74M | 2.47% |
150,600
+81,600
| +118% | +$39.9M |
2023 Q2
1 quarter
|
|
12
Vaxcyte
PCVX
$11B
| $68.5M | 2.28% |
1,342,751
-271,371
| -17% | -$13.4M |
2022 Q4
3 quarters
|
|
|
VRNA
13
DELISTED
Verona Pharma
VRNA
| $65.3M | 2.18% |
4,007,197
-389,919
| -9% | -$7.51M |
2020 Q3
12 quarters
|
|
14
DELISTED
Cymabay Therapeutics
CBAY
| $60.3M | 2.01% |
4,043,191
+309,936
| +8% | +$4.11M |
2022 Q4
3 quarters
|
|
15
MeiraGTx Holdings
MGTX
$997M
| $55.6M | 1.86% |
11,331,103
| – | – |
2018 Q2
21 quarters
|
|
16
Iovance Biotherapeutics
IOVA
$6.6B
| $54.4M | 1.82% |
11,962,938
-2,073,472
| -15% | -$13.5M |
2015 Q1
34 quarters
|
|
17
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $49.9M | 1.66% |
255,151
| – | – |
2020 Q2
13 quarters
|
|
|
18
Amylyx Pharmaceuticals
AMLX
$3.45B
| $49.2M | 1.64% |
2,688,873
-2,185,046
| -45% | -$46.2M |
2022 Q1
6 quarters
|
|
19
BridgeBio Pharma
BBIO
$12.9B
| $46.1M | 1.54% |
1,748,933
| – | – |
2019 Q2
17 quarters
|
|
20
Medtronic
MDT
$118B
| $46M | 1.53% |
587,000
+120,000
| +26% | +$10M |
2023 Q2
1 quarter
|
|
21
Roivant Sciences
ROIV
$25B
| $44.6M | 1.49% |
3,819,456
+687,720
| +22% | +$7.77M |
2022 Q4
3 quarters
|
|
22
Disc Medicine
IRON
$2.32B
| $42.1M | 1.4% |
895,641
+152,803
| +21% | +$7.64M |
2023 Q2
1 quarter
|
|
23
Immatics
IMTX
$1.1B
| $40.4M | 1.35% |
3,491,500
| – | – |
2020 Q3
12 quarters
|
|
|
24
DELISTED
Apogee Therapeutics
APGE
| $38.9M | 1.3% |
+1,827,901
| New | +$40.3M |
2023 Q3
0 quarters
|
|
25
DELISTED
Crinetics Pharmaceuticals
CRNX
| $37.6M | 1.25% |
1,263,732
-683,205
| -35% | -$14.1M |
2018 Q3
20 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $196M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.
- Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
- Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
- Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
- Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
- Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
- Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.
Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.